Cabazitaxel safe and effective in mCRPC
After promising efficacy data from the TROPIC trial (NCT00417079), cabazitaxel was approved for use in metastatic castration-resistant prostate cancer (mCRPC) post-docitaxel therapy. Until now, howeve...
Author: VJOncology
Added: 08/22/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts